Author:

Krista Solano

Dua Lipa is Under Copyright Fire

Singer and songwriter, Dua Lipa has come under two copyright infringement lawsuits over the past month. Both lawsuits allege the pop star’s hit song “Levitating” infringed upon copyrighted work. While the two suits allege infringement against the same song, their outcomes may differ based on the allegation brought forth in each complaint.

Olympics Sponsors Keep Quiet as the 2022 Games Loom

The 2022 Beijing Olympics will reach millions of people around the world. Despite the Games quickly approaching, the most prominent Olympic sponsors have remained silent about the human rights violations in China. The United States announced the decision to diplomatically boycott the games but athletes will compete.

NBA Healthcare Fraud Scheme

Krista Solano Associate Editor Loyola University Chicago School of Law, JD 2023 Eighteen former NBA players were charged with defrauding the league’s health and welfare benefit plan. The former players were charged under 8 USC Section 1347, otherwise known as the federal healthcare fraud statute. The fraud scheme submitted $3.9 million in fake claims, for …
Read more

A Potential Strike May Impact Hollywood

The biggest industry strike among Hollywood production workers since World War II may be impending. On October 4, 2021, the International Alliance of Theatrical Stage Employees (IATSE) announced that members overwhelming granted the union’s president the authorization to strike against the Alliance of Motion Picture and Television Producers (AMPTP). The crux of the demands by the union revolves around increasing workers’ quality of life. Average working days consist of fourteen hours or more, with meal breaks often avoided, leaving little to no personal life outside of the industry.

The New Hope and Frustration for Alzheimer’s Patients

For the first time in about twenty years, the U.S. Food and Drug Administration (FDA) approved a drug to combat the progression of Alzheimer’s. The newly approved drug is manufactured by Biogen and will be called Aduhelm. The FDA granted fast track designation of the drug to speed up access to patients. While Aduhelm will not reverse already developed Alzheimer’s symptoms, it will slow down the advancement of the disease by removing deposits of beta-amyloid, a protein found in early-stage Alzheimer’s patient’s brains.